Breaking news

CIFA: A Year Of Strategic Growth And Opportunity For Investment Funds In 2025

The Cyprus Investment Funds Association (CIFA) is stepping into 2025 with renewed confidence, building on the significant achievements of the past years. Despite the global uncertainties that continue to unfold, Cyprus’ Investment Funds sector has firmly established itself as a vital contributor to the nation’s economic and social prosperity.

In 2024, Cyprus reached a major milestone, surpassing €9.3 billion in assets under management. This remarkable achievement highlights the sector’s impressive growth and resilience. The year also marked an expansion of Cyprus’ global presence, attracting new fund managers and investment opportunities, further cementing its status as a leading European hub for Investment Funds. This success was driven by strategic collaborations and the dedicated efforts of professionals within the sector, fostering the creation of specialized job roles and reinforcing Cyprus’ position as a robust financial centre.

Looking ahead to 2025, CIFA remains fully committed to promoting Cyprus as the premier destination for global investment funds. By working alongside key stakeholders, including the Ministry of Finance, the Cyprus Securities and Exchange Commission, and Invest Cyprus, CIFA aims to enhance the regulatory framework and drive innovative solutions for the industry. The timely approval of pending legislation that modernizes regulatory processes and introduces new investment structures is crucial for unlocking the full potential of the sector. These updates will provide the industry with the necessary tools to stay competitive and aligned with international best practices. CIFA urges all stakeholders to prioritize this agenda to ensure Cyprus continues to attract high-quality investments and talent.

In addition, CIFA recognises the importance of equipping individuals and businesses with essential financial knowledge. In 2025, the association plans to roll out initiatives designed to boost financial literacy across Cyprus. These will include workshops, partnerships, and digital campaigns aimed at enhancing understanding of investment funds and financial planning. By empowering citizens and professionals with the knowledge to make informed financial decisions, CIFA is contributing to the long-term economic resilience of Cyprus.

Maria Panayiotou, President of CIFA, shares her outlook for the year: “The success of the Investment Funds sector is a reflection of our adaptability, innovation, and ability to thrive in a competitive global market. In 2025, our focus will be on sustainability, technology-driven solutions, and strengthening our partnerships across markets. Our goal is to drive economic growth while delivering lasting value for society. With the combined expertise and dedication of our sector, I am confident that we will continue to play a transformative role in Cyprus’ economy, fostering resilience and creating opportunities for all.”

As Cyprus embarks on a year of revitalisation and resilience, CIFA remains steadfast in advocating for the interests of its members, elevating Cyprus on the international stage, and supporting initiatives that promote sustainable development within the financial sector. The association calls on all stakeholders to collaborate in advancing the innovation, sustainability, and resilience that will define Cyprus’ financial future.

Medochemie And Theramir Announce Strategic Investment Agreement To Advance Biotech Manufacturing In Cyprus

Pharmaceutical manufacturer Medochemie and biotechnology company Theramir, both Cyprus-based, have announced a strategic investment agreement and collaboration aimed at developing next-generation biological therapies and expanding manufacturing capabilities in Cyprus.

The agreement, announced on 2 September 2026, brings together Medochemie’s experience in pharmaceutical manufacturing and Theramir’s biotechnology research. The companies said the collaboration would support advanced pharmaceutical manufacturing in Cyprus and south-eastern Europe.

What The Partnership Covers

Medochemie’s contribution will include its expertise in manufacturing sterile therapeutic products and its access to international markets.

Theramir develops technologies based on extracellular vesicles and microRNAs. Its work includes using stem-cell-derived extracellular vesicles to deliver microRNAs, small, non-coding RNA molecules that regulate genes and biological pathways associated with cancer growth and metastasis.

Under the agreement, the companies will jointly support the development of “Good Manufacturing Practice” capabilities for next-generation biological therapies. The partnership is also intended to help move these therapies towards clinical development.

A Wider Role For Cyprus

The collaboration will also support Theramir’s wider research programme. According to the companies, it is intended to strengthen Cyprus’s biotechnology infrastructure and expand local capacity in next-generation biomanufacturing.

They present the agreement as a step towards giving Cyprus a larger role in biotechnology and advanced pharmaceutical manufacturing for south-eastern Europe and international markets.

Aretilaw firm
The Future Forbes Realty Global Properties
Uol
eCredo

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter